We know that development of a good model is a long process of incremental improvements.
GastroPlus® User Group Webinar: Physiologically Based Pharmacokinetic Modelling for First‑In‑Human Predictions
This webinar provides an overview of a recent publication on physiologically based pharmacokinetic (PBPK) modeling in first in human (FIH) predictions, and this was a collaborative effort from GastroPlus® User Group members.
A practical approach to modeling the impact of amorphous drug nanoparticles on the oral absorption of poorly soluble drugs
Recently published studies have proposed that amorphous drug nanoparticles in gastrointestinal fluids may be beneficial for the absorption of poorly soluble compounds.
Feature of the week #68: Scripting Monolix in R
Sometimes you might want to use Monolix through the interface but with scripts, for example to automate a set of actions in Monolix.
Simulations Plus Annual Forum “Partner with the Good Guys” at PharmSci 360
Thank you to everyone who joined us for the Simulations Plus, Inc. Annual Forum at American Association of Pharmaceutical Scientists (AAPS) Pharmsci360 in San Antonio, TX.
Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model
Topiroxostat is a selective xanthine oxidoreductase (XOR) inhibitor for the management of hyperuricemia in patients with or without gout.
Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus
Funded collaborative research effort adds new functionality to the top-rated simulation engine.
Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results
Full-Year Revenue Increased 14.5% to $34 Million
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
Animal models have suggested that the combination of pretomanid with pyrazinamide and moxifloxacin (PaMZ) may shorten TB therapy duration to 3–4 months.
Mechanistic Modelling of the Linkage Between Proximal Tubule Cell Sublethal Injury and Tubular Sodium Reabsorption Impairment
Sublethal renal epithelial cell injury, a key manifestation of drug-induced acute kidney injury (AKI), is characterized by loss of brush border and cellular polarity of proximal tubular cells (PTCs).
Evaluating the Nephrotoxicity of Exemplar Compounds Using a Mechanistic Model of Drug-Induced Acute Kidney Injury
Drug-induced nephrotoxicity is a common source of acute kidney injury (AKI) and a condition that complicates clinical outcomes of vulnerable patients.
Mechanistic Modeling Aids in the Interpretation of Alanine Aminotransferase Elevations Associated with Clinical Ischemic Liver Injury
DILIsym® software can use serial serum alanine aminotransferase (ALT) assessments to predict hepatocyte loss (HL) and corresponding changes in total bilirubin (TBIL) due to...
Case study: PK/PD modeling using the simultaneous, sequential or intermediate approach (Maryland 3)
The aim of this tutorial is to show how to develop a pharmacokinetic-pharmacodynamic (PKPD) model.
Physiologically Based Pharmacokinetic Model for Voriconazole and Prediction of its Interactions with Midazolam and Alfentanil
Voriconazole (formerly known as UK-109,496), is a second-generation triazole antifungal agent widely used in the treatment of invasive fungal infections.
Exploring Clinical Relevance of Dissolution Testing by Physiologically Based Biopharmaceutics Modeling (PBBM)
In vitro dissolution testing, if reflective of in vivo drug release/absorption, is considered a surrogate for in vivo drug performance.
Mechanistic Insights into Drug-Induced Liver Injury for Macrolide Antibiotics using Quantitative Systems Toxicology Modeling
DILIsym Services Is Using QSP and QST Modeling to Predict Efficacy and Safety of Drugs in Development
Predicting Shrinkage of Individual Parameters in More Complex NLME Models Using Bayesian Fisher Information Matrix
When data are sparse, parameters derived from a non-linear mixed effects model analysis...
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call
Conference Call to be on Wednesday, November 13, 2019, at 4:15 PM ET
Development of Drugs to Treat NAFLD/NASH using Quantitative Systems Pharmacology Modeling
This session will provide scientific background and overview of the application of quantitative systems pharmacology (QSP) modeling in drug development to treat NALFD/NASH